Laboratory of Molecular Biology, Transplantation Biology Research Center, Massachusetts General Hospital, MGH-East, Building 149-9019, 13th Street, Boston, MA 02129, USA.
J Immunol. 2010 Mar 1;184(5):2394-400. doi: 10.4049/jimmunol.0803664. Epub 2010 Jan 25.
MHC class II (MHCII) genes have been implicated in the regulation of T lymphocyte responses. However, the mechanism of MHCII-driven regulation remains unknown. Matching for MHCII between donors and recipients of allografts favors regulatory T cell tolerance to transplants and provides a unique opportunity to study this regulation. In this study, we investigated MHCII regulation using transfer of donor MHCII genes in recipients of cardiac allografts. Transfer of MHCII IA(b) genes in the bone marrow of CBA mice (H-2(k)) prior to the grafting of IA(b+) fully allogeneic C57BL/6 (B6, H-2(b)) heart transplants resulted in donor-specific tolerance associated with long-term survival of B6, but not third-party, allografts without sustained immunosuppression. Strikingly, the majority of accepted heart transplants (>170 d) were devoid of allograft vasculopathy. Further studies indicated that intracellular IA(b) initiated the tolerogenic process, which was mediated by regulatory T cells (Tregs) that polarized antigraft responses to Th2 cytokine producers. This mechanism seems to be unique to MHCII genes, because previous MHC class I gene-based therapies failed to produce Tregs. These results demonstrate the key role of MHCII in the induction of Tregs. They also underscore a potential mechanism of specific inactivation of T cells in this model; when activated by IA(b+) grafts, IA(b)-specific Tregs repress the entire alloresponse to C57BL/6 transplants (including MHC I and minor Ags), thus mediating T cell tolerance.
MHC II(MHCII)基因已被牵连到 T 淋巴细胞反应的调节中。然而,MHCII 驱动调节的机制仍然未知。同种异体移植物供体和受者之间 MHCII 的匹配有利于调节性 T 细胞对移植的耐受,并为研究这种调节提供了一个独特的机会。在这项研究中,我们使用心脏同种异体移植物受者中供体 MHCII 基因的转移来研究 MHCII 调节。在 CBA 小鼠(H-2(k))骨髓中移植 MHCII IA(b)基因,然后移植 IA(b+)完全同种异体 C57BL/6(B6,H-2(b))心脏移植物,导致与 B6 但不与第三方同种异体移植物的长期存活相关的供体特异性耐受,而无需持续的免疫抑制。引人注目的是,大多数接受的心脏移植物(>170d)没有同种异体移植物血管病。进一步的研究表明,IA(b) 细胞内启动了耐受过程,该过程由调节性 T 细胞(Tregs)介导,这些 Tregs 将针对移植物的反应极化到 Th2 细胞因子产生者。这种机制似乎是 MHCII 基因所特有的,因为以前基于 MHC 类 I 基因的治疗未能产生 Tregs。这些结果表明 MHCII 在诱导 Tregs 中的关键作用。它们还强调了在这种模型中特定失活 T 细胞的潜在机制;当被 IA(b+)移植物激活时,IA(b)-特异性 Tregs 抑制对 C57BL/6 移植物的整个同种异体反应(包括 MHC I 和次要 Ag),从而介导 T 细胞耐受。